JPWO2021030533A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2021030533A5
JPWO2021030533A5 JP2022509126A JP2022509126A JPWO2021030533A5 JP WO2021030533 A5 JPWO2021030533 A5 JP WO2021030533A5 JP 2022509126 A JP2022509126 A JP 2022509126A JP 2022509126 A JP2022509126 A JP 2022509126A JP WO2021030533 A5 JPWO2021030533 A5 JP WO2021030533A5
Authority
JP
Japan
Prior art keywords
rna
composition
salt
denatured
resin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022509126A
Other languages
Japanese (ja)
Other versions
JP2022544416A (en
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/046069 external-priority patent/WO2021030533A1/en
Publication of JP2022544416A publication Critical patent/JP2022544416A/en
Publication of JPWO2021030533A5 publication Critical patent/JPWO2021030533A5/ja
Pending legal-status Critical Current

Links

Claims (15)

以下、
(a)リボ核酸(RNA)を含む混合物を脱塩して、20mM未満の塩濃度を有する低塩分RNA組成物を産生することと、
(b)前記低塩分RNA組成物を60℃より高い温度に加熱して、変性RNAを産生することと、
(c)前記変性RNAを含む組成物を高塩分緩衝液とインライン混合して、変性RNA及び少なくとも50mMの濃度の塩を含む組成物を産生することと、
(d)(c)で産生された前記組成物の前記変性RNAを40℃未満の温度でオリゴdT樹脂に結合させることと、
(e)前記オリゴdT樹脂からRNAを溶出させることと、
を含む、方法。
below,
(a) desalting a mixture comprising ribonucleic acid (RNA) to produce a low-salt RNA composition having a salt concentration of less than 20 mM;
(b) heating the low-salt RNA composition to a temperature greater than 60° C. to produce denatured RNA;
(c) in-line mixing a composition comprising said denatured RNA with a high salt buffer to produce a composition comprising denatured RNA and salt at a concentration of at least 50 mM;
(d) binding the denatured RNA of the composition produced in (c) to an oligo-dT resin at a temperature below 40°C;
(e) eluting the RNA from the oligo-dT resin;
A method, including
以下、
(a)リボ核酸(RNA)を含む混合物を脱塩して、2mS/cm未満の導電率を有する低塩分RNA組成物を産生することと、
(b)前記低塩分RNA組成物を60℃より高い温度に加熱して、変性RNAを産生することと、
(c)前記変性RNAを含む組成物を高塩分緩衝液とインライン混合して、変性RNA及び少なくとも5mS/cmの導電率を含む組成物を産生することと、
(d)(c)で産生された前記組成物の前記変性RNAを40℃未満の温度でオリゴdT樹脂に結合させることと、
(e)前記オリゴdT樹脂からRNAを溶出させることと、
を含む、方法。
below,
(a) desalting a mixture comprising ribonucleic acid (RNA) to produce a low-salt RNA composition having a conductivity of less than 2 mS/cm;
(b) heating the low-salt RNA composition to a temperature greater than 60° C. to produce denatured RNA;
(c) in-line mixing a composition comprising said denatured RNA with a high salt buffer to produce a composition comprising denatured RNA and a conductivity of at least 5 mS/cm;
(d) binding the denatured RNA of the composition produced in (c) to an oligo-dT resin at a temperature below 40°C;
(e) eluting the RNA from the oligo-dT resin;
A method, including
(a)の前記混合物はin vitro転写反応物である、請求項1または2に記載の方法。 3. The method of claim 1 or 2, wherein said mixture of (a) is an in vitro transcription reaction. (i)(a)及び/または(c)の前記塩はNaClを含む、並びに/あるいは、
(ii)前記高塩分緩衝液は、100mM~1000mMの塩濃度及び/または5mS/cm~85mS/cmの導電率を有する、並びに/あるいは、
(iii)前記低塩分RNA組成物は、1~20mMの塩濃度及び/または0.1~2mS/cmの導電率を有する、並びに/あるいは、
(iv)前記低塩分RNA組成物は、変性剤分子の存在下で加熱され、
任意選択で、前記変性剤分子は、ジメチルスルホキシド、グアニジン、または尿素である、
請求項1~3のいずれか一項に記載の方法。
(i) said salt of (a) and/or (c) comprises NaCl, and/or
(ii) the high salt buffer has a salt concentration of 100 mM to 1000 mM and/or a conductivity of 5 mS/cm to 85 mS/cm, and/or
(iii) the low-salt RNA composition has a salt concentration of 1-20 mM and/or a conductivity of 0.1-2 mS/cm, and/or
(iv) the low-salt RNA composition is heated in the presence of a denaturant molecule;
Optionally, said denaturant molecule is dimethylsulfoxide, guanidine, or urea.
The method according to any one of claims 1-3.
前記脱塩は、前記RNAを疎水性相互作用クロマトグラフィー(HIC)樹脂に結合させることと、前記HIC樹脂から前記RNAを溶出させて、前記低塩分RNA組成物を産生することと、を含
任意選択で、前記HIC樹脂は、2000オングストロームの細孔を有する(ポリ)スチレン-ジビニルベンゼン(PS-DVB)R150ビーズ樹脂である、請求項1~のいずれか一項に記載の方法。
The desalting comprises binding the RNA to a hydrophobic interaction chromatography (HIC) resin and eluting the RNA from the HIC resin to produce the low salt RNA composition. ,
Optionally, the HIC resin is a (poly)styrene-divinylbenzene (PS-DVB) R150 bead resin with 2000 angstrom pores .
(b)の前記加熱は
(i)1分未満、少なくとも10秒間、または、10~60、10~30、20~40、もしくは30~60秒間、並びに/あるいは、
(ii)60℃~90℃の温度で
行われる、
請求項1~のいずれか一項に記載の方法。
The heating of (b) is
(i) less than 1 minute, at least 10 seconds, or 10-60, 10-30, 20-40, or 30-60 seconds , and/or
(ii) at a temperature between 60°C and 90°C
be done,
The method according to any one of claims 1-5 .
(i)前記変性RNAを含む組成物を60℃未満の温度もしくは40℃未満の温度にインライン冷却すること、及び/または、
(ii)前記変性RNAを含む組成物をブレークタンクに保管することを、
(b)と(c)との間にさらに含
任意選択で、前記変性RNAを含む組成物は、2~8℃で1~5日間、前記ブレークタンクに保管される
請求項1~のいずれか一項に記載の方法。
(i) in-line cooling the composition comprising said denatured RNA to a temperature below 60°C or below 40°C , and/or
(ii) storing the composition comprising the denatured RNA in a break tank;
further comprising between (b) and (c);
optionally, the composition comprising said denatured RNA is stored in said break tank at 2-8° C. for 1-5 days ;
A method according to any one of claims 1-6 .
(c)の前記インライン混合は1分未満で行われる、及び/または、
(c)の前記インライン混合は、前記混合物を前記オリゴdT樹脂上に結合させることと並行して行われる
請求項1~のいずれか一項に記載の方法。
said in-line mixing of (c) is performed in less than 1 minute; and/or
the in-line mixing of (c) is performed in parallel with binding the mixture onto the oligo-dT resin ;
A method according to any one of claims 1-7 .
(i)(c)で産生された前記変性RNAを含む組成物は、50~500mMの塩濃度及び/または5~85mS/cmの導電率を有する、並びに/あるいは、
(ii)(c)の前記組成物における全RNAのうちの少なくとも90%が、変性RNAを含む、
請求項1~のいずれか一項に記載の方法。
(i) the composition comprising the denatured RNA produced in (c) has a salt concentration of 50-500 mM and/or a conductivity of 5-85 mS/cm, and/or
(ii) at least 90% of the total RNA in the composition of (c) comprises denatured RNA;
The method according to any one of claims 1-8 .
(i)(d)の前記結合は4℃~25℃の温度及び/または20分未満で行われる、並びに/あるいは、
(ii)前記オリゴdT樹脂は、ポリdTで誘導体化された、2000オングストロームの細孔を有する(ポリ)スチレン-ジビニルベンゼン(PS-DVB)ビーズ樹脂である、並びに/あるいは、
(iii)前記オリゴdT樹脂から溶出された前記RNAは、ポリA鎖含有mRNAを少なくとも90%もしくは少なくとも95%含む、
請求項1~のいずれか一項に記載の方法。
(i) said bonding of (d) is performed at a temperature of 4° C. to 25° C. and/or in less than 20 minutes , and/or
(ii) the oligo-dT resin is a poly-dT-derivatized (poly)styrene-divinylbenzene (PS-DVB) bead resin with 2000 Angstrom pores, and/or
(iii) the RNA eluted from the oligo-dT resin comprises at least 90% or at least 95% poly A chain-containing mRNA;
A method according to any one of claims 1-9 .
前記RNAの二次構造が、(b)の前後で、紫外線検出を用いてモニターされる、及び/または、
(b)中の前記RNAの変性が、紫外線検出を用いてモニターされる、
請求項1~10のいずれか一項に記載の方法。
the secondary structure of said RNA is monitored before and after (b) using ultraviolet detection, and/or
denaturation of the RNA in (b) is monitored using ultraviolet detection;
A method according to any one of claims 1-10 .
以下、
高塩分緩衝液を、変性リボ核酸(RNA)を含む低塩分変性RNA組成物とインラインで混合して、変性RNAを含む高塩分組成物を産生することと、
前記変性RNAをオリゴdT樹脂に結合させることと、
を含む方法。
below,
mixing a high salt buffer in-line with a low salt denatured RNA composition comprising denatured ribonucleic acid (RNA) to produce a high salt composition comprising denatured RNA;
binding the denatured RNA to an oligo-dT resin;
method including.
(i)前記インライン混合は、前記変性RNAを前記オリゴdT樹脂に結合させる前に、1分未満で行われる、及び/または、
(ii)前記結合は20分未満で行われる、
請求項12に記載の方法。
(i) the in-line mixing is performed for less than 1 minute prior to binding the denatured RNA to the oligo-dT resin, and/or
(ii) said binding occurs in less than 20 minutes;
13. The method of claim 12 .
前記オリゴdT樹脂からRNAを低塩分緩衝液中で溶出させることをさらに含
任意選択で、前記オリゴdT樹脂から溶出された前記RNAは、ポリA鎖含有mRNAを少なくとも90%または少なくとも95%含む、
請求項12または13に記載の方法。
further comprising eluting the RNA from the oligo-dT resin in a low salt buffer;
optionally, said RNA eluted from said oligo-dT resin comprises at least 90% or at least 95% poly A strand containing mRNA.
14. A method according to claim 12 or 13 .
(i)高塩分緩衝液とのインライン混合の前に、RNA及び20mM未満の塩濃度を含む組成物を、60℃より高い温度に加熱して、変性RNA組成物を産生すること、または、
高塩分緩衝液とのインライン混合の前に、RNAを含み、2mS/cm未満の導電率を有する組成物を、60℃より高い温度に加熱して、変性RNA組成物を産生すること、並びに/あるいは、
(ii)高塩分緩衝液とのインライン混合の前に、RNAを含む混合物を脱塩して、20mM未満の塩濃度を有するRNA組成物を産生することと、及び、
前記20mM未満の塩濃度を有するRNA組成物を、60℃より高い温度に加熱して、前記変性RNA組成物を産生することと、
をさらに含む、請求項1214のいずれか一項に記載の方法。
(i) heating a composition comprising RNA and a salt concentration of less than 20 mM to a temperature above 60° C. to produce a denatured RNA composition prior to in-line mixing with the high salt buffer ; or
and/ or,
(ii) desalting the RNA-containing mixture prior to in-line mixing with the high salt buffer to produce an RNA composition having a salt concentration of less than 20 mM; and
heating the RNA composition having a salt concentration of less than 20 mM to a temperature greater than 60° C. to produce the denatured RNA composition;
15. The method of any one of claims 12-14 , further comprising
JP2022509126A 2019-08-14 2020-08-13 Processes to Purify Downstream Products of In Vitro Transcription Pending JP2022544416A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962886840P 2019-08-14 2019-08-14
US62/886,840 2019-08-14
PCT/US2020/046069 WO2021030533A1 (en) 2019-08-14 2020-08-13 Processes for purifying downstream products of in vitro transcription

Publications (2)

Publication Number Publication Date
JP2022544416A JP2022544416A (en) 2022-10-18
JPWO2021030533A5 true JPWO2021030533A5 (en) 2023-08-21

Family

ID=74571243

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022509126A Pending JP2022544416A (en) 2019-08-14 2020-08-13 Processes to Purify Downstream Products of In Vitro Transcription

Country Status (8)

Country Link
US (1) US20220348900A1 (en)
EP (1) EP4013865A4 (en)
JP (1) JP2022544416A (en)
CN (1) CN114269918A (en)
AU (1) AU2020329226A1 (en)
BR (1) BR112022002548A2 (en)
CA (1) CA3149498A1 (en)
WO (1) WO2021030533A1 (en)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11364292B2 (en) 2015-07-21 2022-06-21 Modernatx, Inc. CHIKV RNA vaccines
US11564893B2 (en) 2015-08-17 2023-01-31 Modernatx, Inc. Methods for preparing particles and related compositions
WO2017070601A1 (en) 2015-10-22 2017-04-27 Modernatx, Inc. Nucleic acid vaccines for varicella zoster virus (vzv)
WO2017070613A1 (en) 2015-10-22 2017-04-27 Modernatx, Inc. Human cytomegalovirus vaccine
EP3364950A4 (en) 2015-10-22 2019-10-23 ModernaTX, Inc. Tropical disease vaccines
HUE059127T2 (en) 2015-10-22 2022-10-28 Modernatx Inc Respiratory virus vaccines
AU2016366978B2 (en) 2015-12-10 2022-07-28 Modernatx, Inc. Compositions and methods for delivery of therapeutic agents
CN109937253B (en) 2016-09-14 2023-06-30 摩登纳特斯有限公司 High-purity RNA composition and preparation method thereof
WO2018075980A1 (en) 2016-10-21 2018-04-26 Modernatx, Inc. Human cytomegalovirus vaccine
MA46766A (en) 2016-11-11 2019-09-18 Modernatx Inc INFLUENZA VACCINE
EP3555289A1 (en) 2016-12-13 2019-10-23 ModernaTX, Inc. Rna affinity purification
WO2018170245A1 (en) 2017-03-15 2018-09-20 Modernatx, Inc. Broad spectrum influenza virus vaccine
EP3595713A4 (en) 2017-03-15 2021-01-13 ModernaTX, Inc. Respiratory syncytial virus vaccine
US11045540B2 (en) 2017-03-15 2021-06-29 Modernatx, Inc. Varicella zoster virus (VZV) vaccine
WO2018170256A1 (en) 2017-03-15 2018-09-20 Modernatx, Inc. Herpes simplex virus vaccine
US20200030432A1 (en) 2017-03-17 2020-01-30 Modernatx, Inc. Zoonotic disease rna vaccines
MA48047A (en) 2017-04-05 2020-02-12 Modernatx Inc REDUCTION OR ELIMINATION OF IMMUNE RESPONSES TO NON-INTRAVENOUS THERAPEUTIC PROTEINS, FOR EXAMPLE SUBCUTANEOUSLY
US11786607B2 (en) 2017-06-15 2023-10-17 Modernatx, Inc. RNA formulations
EP3668979A4 (en) 2017-08-18 2021-06-02 Modernatx, Inc. Methods for hplc analysis
US11866696B2 (en) 2017-08-18 2024-01-09 Modernatx, Inc. Analytical HPLC methods
CN111212905A (en) 2017-08-18 2020-05-29 摩登纳特斯有限公司 RNA polymerase variants
AU2018326799A1 (en) 2017-08-31 2020-02-27 Modernatx, Inc. Methods of making lipid nanoparticles
US10653767B2 (en) 2017-09-14 2020-05-19 Modernatx, Inc. Zika virus MRNA vaccines
US11911453B2 (en) 2018-01-29 2024-02-27 Modernatx, Inc. RSV RNA vaccines
JP2022521094A (en) 2019-02-20 2022-04-05 モデルナティエックス インコーポレイテッド RNA polymerase variant for co-transcription capping
US11851694B1 (en) 2019-02-20 2023-12-26 Modernatx, Inc. High fidelity in vitro transcription
WO2021213924A1 (en) 2020-04-22 2021-10-28 BioNTech SE Coronavirus vaccine
US11406703B2 (en) 2020-08-25 2022-08-09 Modernatx, Inc. Human cytomegalovirus vaccine
WO2022162027A2 (en) 2021-01-27 2022-08-04 Curevac Ag Method of reducing the immunostimulatory properties of in vitro transcribed rna
WO2022266389A1 (en) * 2021-06-17 2022-12-22 Modernatx, Inc. Alternative rna purification strategies
US11878055B1 (en) 2022-06-26 2024-01-23 BioNTech SE Coronavirus vaccine
WO2024026005A1 (en) * 2022-07-28 2024-02-01 Modernatx, Inc. Methods of rna purification
CN117603958A (en) * 2023-11-23 2024-02-27 江苏耀海生物制药有限公司 Method for purifying in vitro transcribed mRNA and application thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU655766A (en) * 1967-06-06 1968-12-12 William Wake David Bulk handling bin
EP0649908A1 (en) * 1988-07-08 1995-04-26 Cetus Oncology Corporation Uses of gap gene sequences
US5763573A (en) * 1988-08-10 1998-06-09 Chiron Corporation GTPase activating protein fragments
ATE181332T1 (en) * 1989-08-21 1999-07-15 Chiron Corp PEPTIDES DERIVED FROM GTPASE ACTIVATE PROTEIN (GAP) AND THEIR DIAGNOSTIC AND THERAPEUTIC USE
AU673810B2 (en) * 1991-10-16 1996-11-28 Chiron Corporation Secreted Mac-2-binding glycoprotein
EP2971161B1 (en) * 2013-03-15 2018-12-26 ModernaTX, Inc. Ribonucleic acid purification

Similar Documents

Publication Publication Date Title
JPWO2021030533A5 (en)
US20220348900A1 (en) Processes for purifying downstream products of in vitro transcription
US8084032B2 (en) Purification method which prevents denaturation of an antibody
JP2010504738A5 (en)
US20090005543A1 (en) Protein-refolding material
TW202321446A (en) Multicolumn chromatography mrna purification
GB2443505B (en) Nucleic acid purification method
CN105777862A (en) Elution of biomolecules from multi-modal resins using MES and MOPS as mobile phase modifiers
US20140128577A1 (en) Purification of chimeric protein
US5278284A (en) Protein purification method
JP2012510500A5 (en)
EP2748180B1 (en) Protein purification by anion exchange chromatography
JP2013194054A5 (en)
RU2013112276A (en) METHOD FOR PRODUCING IgG COMPOSITION BY HEAT PROCESSING
de la Llosa et al. On the mechanism of reversible inactivation of luteinizing hormone by urea
CA3020959A1 (en) Device and process for isolating nucleic acids from whole blood
JP2007523883A5 (en)
KR100320394B1 (en) Method for Purifying Vitamin-K-dependent Protein by Membrane Chromatography
RU2022106276A (en) METHODS FOR PURIFICATION OF SUBSEQUENT TRANSCRIPTION PRODUCTS IN VITRO
JP4865569B2 (en) Purification method of protein expressed in bacteria
US20230142167A1 (en) A method of single strand rna purification employing an anion exchanger
JP3251545B2 (en) Sperm motility promoting high molecular protein
CN107903301A (en) A kind of separation method for glycosylating albumen
JPWO2021209595A5 (en)
CN106674422A (en) Painting mist purifying coagulant